• Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, reported Phase III results and pooled Phase III analyses supporting the use of DPP-4 Trajenta (linagliptin) in Type II diabetes, including patients who are elderly and those at with diabetic nephropathy. Data were presented at the European Association for the Study of Diabetes meeting in Berlin.

• Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, reported that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. Results from that subanalysis were published in The Lancet.

• Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, reported that canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for Type II diabetes and who are considered to be at greater risk for cardiovascular disease. Data were presented at the European Association for the Study of Diabetes meeting in Berlin. Canagliflozin is a sodium glucose co-transporter 2 inhibitor.

• Merck & Co. Inc., of Whitehouse Station, N.J., said a study of nearly 200,000 young females who received the quadrivalent human papillomavirus vaccine (HPV4) found that immunization was associated only with same-day syncope (fainting) and skin infections in the two weeks after vaccination. The company said those findings supported the general safety of routine vaccine with HPV4 in a clinical care setting to prevent cervical and other genital and reproductive cancers. The study was published in the Archives of Pediatrics & Adolescent Medicine.